An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
Latest Information Update: 25 Dec 2023
At a glance
- Drugs Navtemadlin (Primary) ; Dasatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kartos Therapeutics
- 22 Dec 2023 This trial has been discontinued in Italy.
- 01 Oct 2023 This trial has been discontinued at Hungary (Global end date: 14 Sep 2023).
- 04 Mar 2022 Planned number of patients changed from 133 to 109.